• Email:sales@AmericanPharmaWholesale.com
  • Site Map




Please email us at Sales@AmericanPharmaWholesale.com with our item No, NDC#, UPC# or best is product link. We are located in Oceanside, California. Search over 100,000 items by Name, Item No., NDC, UPC (without dashes) or by Mfg.Name.


Menu

Rx Item-LUXTURNA- voretigene neparvovec-rzyl kit BY Spark Therapeutics

RX71394-415-01Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop

Rx Item-LUXTURNA- voretigene neparvovec-rzyl kit BY Spark Therapeutics

$0.00

LUXTURNA- voretigene neparvovec-rzyl kit BY Spark Therapeutics (voretigene neparvovec) Intraocular Suspension for Subretinal Injection NDC No. 71394-0415-01 71394-415-01 71394041501 7139441501 UPC/GTIN 3-71394-41501-6 371394-415016 371394415016 No. MPN No.415016 Only Lic.-Physician, Pharmacy, Dentist, Drug Mfg, Dist., Gov, Hospital, Lic.Lab, Naturalist, Naturopath, NP, Optometrist, & Pharmacist, PA, Physical Therapist, Podiatrist, Research Co., Uni., VA, Vet & Wholesalers In Scope Of their

Have a question?

  Out of stock. Please use: Have a question? or email at sales@AmericanPharmaWholesale.com for current price and availability.

For: Biallelic RPE65-Mediated Inherited Retinal Disease

Luxturna (voretigene neparvovec) is an adeno-associated viral (AAV) vector gene therapy for the treatment of patients with vision loss due to confirmed biallelic RPE65-mediated inherited retinal disease (IRD). Each carton of LUXTURNA (NDC 71394 415-01) contains one single-dose vial of the LUXTURNA (NDC 71394 065-01, 0.5 mL extractable volume) and two vials of Diluent (NDC 71394 716-01, 1.7 mL extractable volume in each vial). LUXTURNA contains 5 x 1012 vector genomes (vg) per mL, requires a 1:10 dilution prior to administration.


Store LUXTURNA and Diluent frozen at ? -65 C.


Following thaw of the vials, store at room temperature. Store diluted LUXTURNA at room temperature [See Dosage and Administration 2.2].


LUXTURNA is an adeno-associated virus vector-based gene therapy. Follow universal biohazard precautions for handling. These highlights do not include all the information needed to use LUXTURNA safely and effectively. See full prescribing information for LUXTURNA.
LUXTURNA (voretigene neparvovec-rzyl) intraocular suspension for subretinal injection
Initial U.S. Approval: 2017
INDICATIONS AND USAGE

LUXTURNA is an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells as determined by the treating physician(s). (1)
DOSAGE AND ADMINISTRATION

For subretinal injection only.

The recommended dose of LUXTURNA for each eye is 1.5 x 1011 vector genomes (vg), administered by subretinal injection in a total volume of 0.3 mL. (2.1)
Perform subretinal administration of LUXTURNA to each eye on separate days within a close interval, but no fewer than 6 days apart. (2.1)
Recommend systemic oral corticosteroids equivalent to prednisone at 1 mg/kg/day (maximum of 40 mg/day) for a total of 7 days (starting 3 days before administration of LUXTURNA to each eye), and followed by a tapering dose during the next 10 days. (2.1)

DOSAGE FORMS AND STRENGTHS

LUXTURNA is a suspension for subretinal injection, supplied in a 0.5 mL extractable volume in a single-dose 2 mL vial for a single administration in one eye. The supplied concentration (5x1012vg/mL) requires a 1:10 dilution prior to administration. The Diluent is supplied in two single-use 2-mL vials. (3)
CONTRAINDICATIONS

None. (4)
WARNINGS AND PRECAUTIONS

Endophthalmitis: Use proper aseptic injection technique and monitor for signs and symptoms of infection. (5.1)
Permanent decline in visual acuity: Monitor for visual disturbances. (5.2)
Retinal abnormalities: Monitor for macular abnormalities, retinal tears or breaks. Do not inject in the immediate vicinity of the fovea. (5.3)
Increased intraocular pressure: Monitor and manage intraocular pressure elevations. (5.4)
Expansion of intraocular air bubbles: Air travel and/or scuba diving is not recommended until any intraocular air bubbles have been absorbed. (5.5)
Cataract: Subretinal injection of LUXTURNA may result in cataract formation or increase in the rate of cataract progression. (5.6)

ADVERSE REACTIONS

The most common adverse reactions (incidence ? 5%) in the clinical trials were conjunctival hyperemia, cataract, increased intraocular pressure, retinal tear, dellen (thinning of the corneal stroma), macular hole, subretinal deposits, eye inflammation, eye irritation, eye pain, and maculopathy (wrinkling on the surface of the macula). (6)

To report SUSPECTED ADVERSE REACTIONS, contact Spark Therapeutics, Inc. at 1-855-SPARKTX, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
USE IN SPECIFIC POPULATIONS

Pediatric use: Use in infants under 12 months of age is not recommended because of potential dilution or loss of LUXTURNA after administration due to the active retinal cells proliferation occurring in this age group. (8.4)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 12/2019

RX71394-415-01
Rx Item-LUXTURNA- voretigene neparvovec-
RX71394-415-01

Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.
Rx Item-LUXTURNA- voretigene neparvovec-
Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.

Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop
AmericanPharmaWholesale.com
Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop